iBio, Inc. Common Stock - Asset Resilience Ratio
iBio, Inc. Common Stock (IBIO) has an Asset Resilience Ratio of 33.44% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. For the complete balance sheet picture, see iBio, Inc. Common Stock assets under control.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2023)
This chart shows how iBio, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read IBIO total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down iBio, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. See IBIO days of operational coverage to measure how many days the company can operate on defensive assets alone.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $21.46 Million | 33.44% |
| Total Liquid Assets | $21.46 Million | 33.44% |
Asset Resilience Insights
- Very High Liquidity: iBio, Inc. Common Stock maintains exceptional liquid asset reserves at 33.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
iBio, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare iBio, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 22.98% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 2.81% |
Annual Asset Resilience Ratio for iBio, Inc. Common Stock (2013–2023)
The table below shows the annual Asset Resilience Ratio data for iBio, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-06-30 | 0.00% | $0.00 | $41.21 Million | -- |
| 2022-06-30 | 10.91% | $10.85 Million | $99.41 Million | -2.41pp |
| 2021-06-30 | 13.32% | $19.57 Million | $146.97 Million | -- |
| 2020-06-30 | 0.00% | $0.00 | $94.19 Million | -- |
| 2018-06-30 | 0.00% | $0.00 | $43.08 Million | -- |
| 2017-06-30 | 0.00% | $0.00 | $36.01 Million | -- |
| 2016-06-30 | 0.00% | $0.00 | $51.60 Million | -- |
| 2015-06-30 | 0.00% | $0.00 | $12.49 Million | -- |
| 2014-06-30 | 0.00% | $0.00 | $6.49 Million | -- |
| 2013-06-30 | 0.00% | $0.00 | $9.35 Million | -- |
About iBio, Inc. Common Stock
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu,… Read more